Evidence map›Paper›PMID 41413734›Full record

ArticleCommunications biology2025

Pan-cancer analysis reveals TREM1

Yangjie Cai, Shanhang Li, Hening Li, Zhuan Zou, Xinda Zheng, Haijun Tang, Mingxiu Yang, Pintian Wang, Weizhen Wu, Hongcai Teng and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yangjie Cai *Department of Traumatic Orthopedic and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shanhang Li *Department of Bone and Soft Tissue Surgery, The Affiliated Tumor Hospital, Guangxi Medical University, Nanning, China.
Hening Li *Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhuan Zou *Department of Spine and Osteopathic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xinda ZhengDepartment of Traumatic Orthopedic and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Haijun TangDepartment of Spine and Osteopathic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Mingxiu YangDepartment of Spine and Osteopathic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Pintian WangDepartment of Traumatic Orthopedic and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Weizhen WuDepartment of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Hongcai TengDepartment of Spine and Osteopathic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Kai LuoDepartment of Spine and Osteopathic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xinyu HuangDepartment of Spine and Osteopathic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Wenyu FengDepartment of Bone and Joint Surgery and Sports medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shijie LiaoDepartment of Traumatic Orthopedic and Hand Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. gxliaoshijie@163.com.ORCID http://orcid.org/0000-0002-3094-0883
Juliang HeDepartment of Bone and Soft Tissue Surgery, The Affiliated Tumor Hospital, Guangxi Medical University, Nanning, China. hejuliang@gxmu.edu.cn.ORCID http://orcid.org/0009-0001-1841-5584
Yun LiuDepartment of Spine and Osteopathic Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. liuyun@gxmu.edu.cn.ORCID http://orcid.org/0000-0002-7745-1083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are crucial mediators of tumor-induced immunosuppression, while their heterogeneity and spatial dynamics across malignancies remain poorly understood. By integrating single-cell RNA sequencing data from 576 samples across 19 cancer types and spatial transcriptomics data from three distinct malignancies, we identified a PMN-MDSC population. This cell population demonstrated characteristic upregulation of immunosuppressive genes and was associated with poor prognosis across multiple cancer cohorts. Notably, TREM1 was highly expressed in PMN-MDSCs and may mediate immunosuppressive processes. Multiplex immunofluorescence demonstrated that TREM1

Indexed as

Immune ToleranceMyeloid-Derived Suppressor CellsNeoplasmsTriggering Receptor Expressed on Myeloid Cells-1Tumor MicroenvironmentGene Expression Regulation, NeoplasticHumansNeutrophilsSingle-Cell AnalysisTREM1 protein, humanTriggering Receptor Expressed on Myeloid Cells-1

Identifiers

PMID41413734
PMCPMC12820143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.